Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.45 CAD
Change Today 0.00 / 0.00%
Volume 0.0
TST On Other Exchanges
Symbol
Exchange
TST is not on other exchanges.
As of 3:59 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

telesta therapeutics inc (TST) Snapshot

Open
C$0.47
Previous Close
C$0.45
Day High
C$0.47
Day Low
C$0.44
52 Week High
08/28/15 - C$0.54
52 Week Low
11/7/14 - C$0.18
Market Cap
77.2M
Average Volume 10 Days
1.7M
EPS TTM
C$0.07
Shares Outstanding
171.6M
EX-Date
--
P/E TM
6.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for TELESTA THERAPEUTICS INC (TST)

Related News

No related news articles were found.

telesta therapeutics inc (TST) Related Businessweek News

No Related Businessweek News Found

telesta therapeutics inc (TST) Details

Telesta Therapeutics Inc., a late clinical stage biopharmaceutical company, engages in the development, manufacture, marketing, and licensing/acquisition of proprietary and therapeutic products for the human health markets worldwide. Its lead product, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) suspension, is a complex biologic immunotherapy/immunomodulator designed for the treatment of non-muscle-invasive bladder cancer in humans, which has completed Phase III clinical trials. The company was formerly known as Bioniche Life Sciences Inc. and changed its name to Telesta Therapeutics Inc. in November 2014. Telesta Therapeutics Inc. was founded in 1979 and is headquartered in Belleville, Canada.

Founded in 1979

telesta therapeutics inc (TST) Top Compensated Officers

Chief Executive Officer, Chief Scientist and ...
Total Annual Compensation: C$256.3K
Founder, Chairman Emeritus and Board Observer
Total Annual Compensation: C$132.6K
Chief Financial Officer
Total Annual Compensation: C$225.0K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: C$130.0K
Vice President of Manufacturing Operations
Total Annual Compensation: C$201.6K
Compensation as of Fiscal Year 2014.

telesta therapeutics inc (TST) Key Developments

Telesta Therapeutics Receives FDA BLA Filing Notification Letter and Priority Review Designation for MCNA

Telesta Therapeutics Inc. announced that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration (FDA). This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing. In the same letter, the FDA communicated that it has designated the file for 6 month Priority Review and has set February 27, 2016 as the review goal date for MCNA. The FDA has also advised that it will be organizing an advisory committee to discuss the BLA application.

Telesta Therapeutics Inc. Announces South Korean Partnership for MCNA

Telesta Therapeutics Inc. announced that it has entered into an exclusive license, supply and distribution agreement with BL&H Co. Ltd. for the commercialisation of MCNA1 in South Korea. Under the terms of this partnership, Telesta will receive a combination of upfront payments, regulatory milestones and sales milestones in excess of $2 million in addition to a significant transfer price, allowing Telesta to receive a large proportion of the revenue related to MCNA sales in South Korea. Telesta will be responsible for the manufacturing and supply of the drug product, while BL&H will cover all costs for registration, sales and marketing in the territory.

Telesta Therapeutics Inc. Submits Biologics License Application (BLA) to the U.S. FDA

Telesta Therapeutics Inc. announced that it has submitted electronically, through its U.S. agent, a Biologics License Application to the United States Food and Drug Administration for MCNA1. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. Telesta also announced that they have received from the FDA a waiver exempting Telesta from the payment of the USD 2.3 million BLA application fee. The FDA has a 60-day filing review period to determine whether Telesta's BLA submission for MCNA is complete and acceptable for filing, whether MCNA will be designated for priority review or standard review and whether an advisory committee meeting will be scheduled. Their decisions on these items will be communicated to Telesta in the FDA's official filing communication known as the 'Day-74 letter'. Telesta will communicate the FDA's filing decisions upon receipt.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TST:CN C$0.45 CAD 0.00

TST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TST.
View Industry Companies
 

Industry Analysis

TST

Industry Average

Valuation TST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 396.3x
Price/Book NM Not Meaningful
Price/Cash Flow 3.5x
TEV/Sales 579.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELESTA THERAPEUTICS INC, please visit www.telestatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.